ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024
AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.
Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 18 citations in OpenAlex.
- Cortical thickness signature of early-onset Alzheimer's disease across clinical stages and A/T1 biomarker profiles.Journal of neurology · 2026Article
- The tau biomarker cascade is condensed in Down syndrome compared with sporadic Alzheimer's disease.Brain : a journal of neurology · 2026Article
- Facial feature removal in magnetic resonance imaging scans of adults with Down syndrome: A de-facing methodological study.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Promoting Research Excellence in Down Syndrome: Proceedings of the 5th International Conference of the Trisomy 21 Research Society.Neuromolecular medicine · 2026Article
- Combining blood biomarkers and the German version of the Dementia Screening Questionnaire for Individuals with Intellectual Disabilities (DSQIID-G) for diagnosing cognitive decline in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026Article
- Towards pharmacological prevention of Alzheimer disease.Nature reviews. Neurology · 2025Review
- Joint spatial associations of amyloid beta and tau pathology in Down syndrome and preclinical Alzheimer's disease: Cross-sectional associations with early cognitive impairments.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- The Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS): A 10-year report.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Article
- Eye Tracking as a Tool for Detecting Alzheimer's Disease in People With Down Syndrome.Journal of intellectual disability research : JIDR · 2025Article
- Behavioral and psychological symptoms of dementia and Alzheimer's disease progression in Down syndrome.Journal of neurodevelopmental disorders · 2025Article
- Resistance and resilience to Alzheimer's disease in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Cholinergic System Structure and Function Changes in Individuals with Down Syndrome During the Development of Alzheimer's Disease.Current topics in behavioral neurosciences · 2025Review
- Timeline to symptomatic Alzheimer's disease in people with Down syndrome as assessed by amyloid-PET and tau-PET: a longitudinal cohort study.The Lancet. Neurology · 2024Observational
- Assessing amyloid PET positivity and cognitive function in Down syndrome to guide clinical trials targeting amyloid.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- Cerebrovascular disease emerges with age and Alzheimer's disease in adults with Down syndrome.Scientific reports · 2024Article
- AT(N) biomarker profiles and Alzheimer's disease symptomology in Down syndrome.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024Article
- The impact of congenital heart disease on the timing of Alzheimer's disease in Down syndrome.Alzheimer's & dementia (Amsterdam, Netherlands)Article
- Systematic review and evidence gap mapping of Alzheimer's disease biomarker studies in those with intellectual and developmental disability.Alzheimer's & dementia (Amsterdam, Netherlands)Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 2 countries.
Funding
Abstract
introductionDown syndrome (DS) is a genetic cause of early-onset Alzheimer's disease (AD). The National Institute on Aging-Alzheimer's Association AT(N) Research Framework is a staging model for AD biomarkers but has not been assessed in DS.
methodData are from the Alzheimer's Biomarker Consortium-Down Syndrome. Positron emission tomography (PET) amyloid beta (Aβ; 15 mCi of [
resultsAnalyses included 162 adults with DS (aged M = 38.84 years, standard deviation = 8.41). Overall, 69.8% of participants were classified as A-/T-/(N)-, 11.1% were A+/T-/(N)-, 5.6% were A+/T+/(N)-, and 9.3% were A+/T+/(N)+. Participants deemed cognitively stable were most likely to be A-T-(N)- and A+T-(N)-. Tau PET (T+) most closely aligning with memory impairment and AD clinical status. DISCUSSION: Findings add to understanding of AT(N) biomarker profiles in DS. HIGHLIGHTS: Overall, 69.8% of adults with Down syndrome (DS) aged 25 to 61 years were classified as amyloid (A)-/tau (T)-/neurodegeneration (N)-, 11.1% were A+/T-/(N)-, 5.6% were A+/T+/(N)-, and 9.3% were A+/T+/(N)+. The AT(N) profiles were associated with clinical Alzheimer's disease (AD) status and with memory performance, with the presence of T+ aligned with AD clinical symptomology. Findings inform models for predicting the transition to the prodromal stage of AD in DS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.